An extended phase Ib study of epertinib, an orally active reversible dual EGFR/HER2 tyrosine kinase inhibitor, in patients with solid tumours.

Autor: Arkenau, H.-T.1,2, Italiano, A.3, Mak, G.1, Toulmonde, M.3, Baird, R.D.4, Garcia-Corbacho, J.4, Plummer, R.5, Flynn, M.2, Forster, M.2, Wilson, R.H.6, Tosi, D.7, Adenis, A.8, Donaldson, K.9, Posner, J.9, Kawabata, I.9, Arimura, A.9, Deva, S.10, Spicer, J.1,10 james.spicer@kcl.ac.uk
Zdroj: European Journal of Cancer. Nov2018, Vol. 103, p17-23. 7p.
Databáze: Academic Search Ultimate
Externí odkaz: